Blog
Tumor marker CA-19-9: not only about pancreatic cancer, or what this analysis really shows
Tumor markers — are biochemical signals that can help a doctor notice in time that a pathological process is taking place in the body. One of the most famous among them is CA-19-9 — a carboantigen, which is considered a classic indicator of pancreatic cancer. However, in practice, this marker has a much wider application, and its correct interpretation requires caution, experience and context.
What is CA-19-9 from a biological point of view?
CA-19-9 — is a glycoprotein that is normally present in epithelial cells of the gastrointestinal tract, gallbladder, and salivary glands. Its level in the blood increases sharply in the presence of an active proliferative process — a tumor, chronic inflammation, or mechanical obstruction of the biliary tract.
Interestingly, this marker is not completely universal: about 71% of people do not have the Lewis antigen enzymatic system, so their CA-19-9 level will be zero even if they have a tumor.
What can cause an increase in CA-19-9, besides oncology?
High levels of CA-19-9 may be a result of:
obstructive jaundice (gallstones, cholangitis)
cirrhosis or hepatitis (including alcoholic)
pancreatitis (especially chronic)
chronic gastritis or stomach ulcer
benign cysts or polyps in the intestines
And only after excluding these conditions can the doctor consider a tumor marker as evidence of a tumor process.
Dynamics of CA-19-9 levels in clinical observation
A single result is of limited value. The most clinically important thing is the dynamics: does the marker increase after surgery, decrease during treatment, or increase again after six months. For example, if after tumor resection the level of CA-19-9 decreases to normal, and then gradually increases, this may indicate recurrence or metastasis. On the contrary, a consistently low or zero level is a good prognostic sign.
Interpretation of CA-19-9 levels in the clinic
| Level (IU/mL) | Possible value |
|---|---|
| Up to 37 | Normal variant (negative result) |
| 38–100 | Possible inflammatory processes or early stage |
| 101–999 | Tumor process is possible but not confirmed |
| Over 1000 | High probability of malignant process |
How to prepare for the analysis?
The patient is recommended to:
to donate blood on an empty stomach
avoid fatty foods and alcohol the day before the test
do not smoke 2 hours before donating blood
inform the doctor about taking medications, especially choleretic drugs
Also important: the test should not be taken during acute cholecystitis or attacks of biliary colic, as the level may be falsely elevated.
Clinical case example: why dynamics are important
A 58-year-old man complained of weight loss, weakness, and abdominal pain. CT scan revealed a tumor in the head of the pancreas. The CA-19-9 level was 950 U/ml. After surgery and chemotherapy, the marker decreased to 40 U/ml. A year later, it increased to 240 U/ml, which was accompanied by visualization of tumor recurrence. This example demonstrates: the analysis has real clinical value only in combination with medical support.
How is CA-19-9 different from other tumor markers?
Unlike CA-125 (ovarian cancer) or PSA (prostate cancer), CA-19-9 has lower specificity and requires more careful interpretation. It is not used as the sole method of confirming the diagnosis, but is valuable as part of comprehensive cancer surveillance.
When is it appropriate to hand in this marker?
if you have symptoms or imaging findings suggestive of pancreatic or bile duct cancer
for monitoring patients with an established diagnosis (before, during and after treatment)
in patients with suspected abdominal metastases
to assess the effectiveness of targeted or chemotherapy
Sources
CA-19-9 is a tool that does not work on its own, but in the right clinical combination can be a marker of changes that truly save lives.
